NPI: 1497000947 · OCALA, FL 34472 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 07/20/2012
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 07/20/2012 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 13,917 | $2.25M |
| 2019 | 21,597 | $3.21M |
| 2020 | 19,454 | $2.57M |
| 2021 | 10,710 | $1.55M |
| 2022 | 4,352 | $763K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 20,727 | 1,534 | $3.23M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 23,594 | 1,043 | $3.11M |
| J1270 | Injection, doxercalciferol, 1 mcg | 12,895 | 917 | $1.85M |
| J1756 | Injection, iron sucrose, 1 mg | 5,034 | 896 | $699K |
| A4657 | Syringe, with or without needle, each | 2,452 | 1,197 | $632K |
| 85041 | 1,238 | 905 | $188K | |
| 85048 | 1,234 | 902 | $187K | |
| 83970 | 968 | 731 | $160K | |
| 82728 | 477 | 364 | $73K | |
| 83550 | 478 | 365 | $70K | |
| 83540 | 478 | 365 | $70K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 203 | 120 | $31K |
| 82607 | 92 | 71 | $12K | |
| 82746 | 92 | 71 | $12K | |
| 90674 | 31 | 29 | $7K | |
| G0008 | Administration of influenza virus vaccine | 37 | 32 | $7K |